Am J Psychiatry 156:990-999, July 1999
© 1999 American Psychiatric Association
Evidence of Clozapine's Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials
Kristian Wahlbeck, M.D., Ph.D.,
Maxim Cheine, M.D.,
Adib Essali, M.D., Ph.D., M.R.C.Psych., and
Clive Adams, M.B., B.Ch., B.A.O., M.R.C.Psych., M.Sc.(Epid.)
OBJECTIVE: The purpose of this study was to evaluate all available trial-based evidence on the effectiveness of clozapine in schizophrenia as compared with conventional neuroleptics. METHOD: All randomized, controlled trials comparing clozapine with a conventional neuroleptic in which there was satisfactory concealment of patients' treatment allocation were located through electronic searches in all languages of several databases and through contacting authors of recent trials as well as the manufacturer of clozapine. At least two independent reviewers assessed trials for inclusion in the study and extracted data for meta-analysis. RESULTS: The review included 2,530 randomly assigned participants in 30 trials, most of them short-term. Clozapine-treated patients showed more clinical improvement and experienced significantly fewer relapses during treatment, although the risk of blood dyscrasias in long-term treatment may be as high as 7%. Scores on symptom rating scales showed greater improvement among clozapine-treated patients, who were also more satisfied with their treatment. However, there was no evidence that the superior clinical effect of clozapine is reflected in levels of functioning; on the other hand, global functional and pragmatic outcomes were frequently not reported. Clinical improvement was most pronounced in patients with treatment-resistant illness. CONCLUSIONS: This meta-analysis confirms that clozapine is more effective than conventional neuroleptics in reducing symptoms of patients with both treatment-resistant and nonresistant schizophrenia. Future trials should be long-term pragmatic community trials or should address the effectiveness of clozapine in special patient populations. An international standard set of outcomes, including pragmatic assessments of functioning, would greatly enhance the comparison and summation of trials and future assessments of effectiveness.
This article has been cited by other articles:
|
|
|
|
 
M. S. Swartz
Introduction to the CATIE Special Section
Psychiatr Serv,
May 1, 2008;
59(5):
497 - 499.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman
What CATIE Found: Results From the Schizophrenia Trial
Psychiatr Serv,
May 1, 2008;
59(5):
500 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Barbui, A. Signoretti, S. Mule, M. Boso, and A. Cipriani
Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?
Schizophr Bull,
April 23, 2008;
(2008)
sbn030v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chan and M. Sweeting
Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence
J Psychopharmacol,
August 1, 2007;
21(6):
657 - 664.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. M Picchioni and R. M Murray
Schizophrenia
BMJ,
July 14, 2007;
335(7610):
91 - 95.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Tamminga and J. M. Davis
The Neuropharmacology of Psychosis
Schizophr Bull,
July 1, 2007;
33(4):
937 - 946.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Silverstein
Integrating Jungian and Self-Psychological Perspectives Within Cognitive-Behavior Therapy for a Young Man With a Fixed Religious Delusion
Clinical Case Studies,
June 1, 2007;
6(3):
263 - 276.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. S. Masand
Differential pharmacology of atypical antipsychotics: Clinical implications
Am. J. Health Syst. Pharm.,
January 15, 2007;
64(2_Supplement_1):
S3 - S8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman
Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1069 - 1072.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Focus,
September 1, 2006;
4(4):
539.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Wood, G. E. Berger, M. Lambert, P. Conus, D. Velakoulis, G. W. Stuart, P. Desmond, P. D. McGorry, and C. Pantelis
Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study.
Arch Gen Psychiatry,
September 1, 2006;
63(9):
969 - 976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Grass, M. Hellmich, F. M. Leweke, H. Y. Meltzer, A. E. A. Yagcioglu, B. B. K. Akdede, S. L. Gerson, W. G. Honer, A. E. Thornton, G. W. MacEwan, et al.
Clozapine alone versus clozapine and risperidone for refractory schizophrenia.
N. Engl. J. Med.,
April 27, 2006;
354(17):
1846 - 1848.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Am J Psychiatry,
April 1, 2006;
163(4):
611 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, et al.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
N. Engl. J. Med.,
September 22, 2005;
353(12):
1209 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Kerwin and A. Bolonna
Management of clozapine-resistant schizophrenia
Advan. Psychiatr. Treat.,
March 1, 2005;
11(2):
101 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Josiassen, A. Joseph, E. Kohegyi, S. Stokes, M. Dadvand, W. W. Paing, and R. A. Shaughnessy
Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Am J Psychiatry,
January 1, 2005;
162(1):
130 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Woerner, D. G. Robinson, J. Ma. J. Alvir, B. B. Sheitman, J. A. Lieberman, and J. M. Kane
Clozapine as a First Treatment for Schizophrenia
Am J Psychiatry,
August 1, 2003;
160(8):
1514 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. MONCRIEFF
Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination
The British Journal of Psychiatry,
August 1, 2003;
183(2):
161 - 166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis, N. Chen, and I. D. Glick
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Arch Gen Psychiatry,
June 1, 2003;
60(6):
553 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. DUGGAN, J. WARNER, M. KNAPP, and R. KERWIN
Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK
The British Journal of Psychiatry,
June 1, 2003;
182(6):
505 - 508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leucht, G. Pitschel-Walz, R. R. Engel, and W. Kissling
Amisulpride, an Unusual ""Atypical"" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Am J Psychiatry,
February 1, 2002;
159(2):
180 - 190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Geddes
Prevention of Relapse in Schizophrenia
N. Engl. J. Med.,
January 3, 2002;
346(1):
56 - 58.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Wang, O. Demler, and R. C. Kessler
Adequacy of Treatment for Serious Mental Illness in the United States
Am J Public Health,
January 1, 2002;
92(1):
92 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. Bouman and G. Pinner
Use of atypical antipsychotic drugs in old age psychiatry
Advan. Psychiatr. Treat.,
January 1, 2002;
8(1):
49 - 58.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. McKenna, P. Bebbington, and J. Geddes
Atypical antipsychotics
Psychiatr. Bull.,
January 1, 2002;
26(1):
36 - 37.
[Full Text]
|
|
|
|
|
|
|
D. Lyons and D. M McLoughlin
Recent advances: Psychiatry
BMJ,
November 24, 2001;
323(7323):
1228 - 1231.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. R. Pal
Patients with schizophrenia found that clozapine improved their wellbeing without resulting in extrapyramidal motor side effects
Evid. Based Ment. Health,
November 1, 2001;
4(4):
125 - 125.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Bustillo, J. Lauriello, W. P. Horan, and S. J. Keith
The Psychosocial Treatment of Schizophrenia: An Update
Am J Psychiatry,
February 1, 2001;
158(2):
163 - 175.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. J Baldessarini
Review: newer drugs have not yet been shown to be better than clozapine for schizophrenia
Evid. Based Ment. Health,
February 1, 2001;
4(1):
23 - 23.
[Full Text]
|
|
|
|
|
|
|
D. Taylor, L. Shapland, G. Laverick, J. Bond, and J. Munro
Clozapine - a survey of patient perceptions
Psychiatr. Bull.,
December 1, 2000;
24(12):
450 - 452.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Rastogi and L. Mynors-Wallis
Outcome of clozapine treatment for patients with treatment-resistant schizophrenia in a local clinical service
Psychiatr. Bull.,
April 1, 2000;
24(4):
127 - 129.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
OTHER ARTICLES NOTED
Evid. Based Ment. Health,
February 1, 2000;
3(1):
8 - 8.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
